Tango Therapeutics Reports Q3 2026 GAAP EPS of -$0.39
Tango Therapeutics (TNGX) reported a significant financial downturn for the third quarter ended September 30, 2026. The company recorded a net loss of $68.4 million, resulting in a GAAP earnings per share (EPS) of -$0.39. This represents a sharp reversal from the same period in 2025, when the company reported a net income of $15.9 million and an EPS of $0.13 per share. The shift highlights increased spending or operational challenges during the current fiscal year.
Tickers: $TNGX
Topics: earnings GAAP EPS net loss
Read the full article at Seeking Alpha
Part of the story OnKure Therapeutics Reports Q3 GAAP EPS of -$0.36 and Strong Cash Runway (7 articles)